145 related articles for article (PubMed ID: 37379494)
21. Analysis of lung cancer risk model (PLCO
Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
[TBL] [Abstract][Full Text] [Related]
22. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
24. Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer.
Choi E; Sanyal N; Ding VY; Gardner RM; Aredo JV; Lee J; Wu JT; Hickey TP; Barrett B; Riley TL; Wilkens LR; Leung AN; Le Marchand L; Tammemägi MC; Hung RJ; Amos CI; Freedman ND; Cheng I; Wakelee HA; Han SS
J Natl Cancer Inst; 2022 Jan; 114(1):87-96. PubMed ID: 34255071
[TBL] [Abstract][Full Text] [Related]
25. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
[TBL] [Abstract][Full Text] [Related]
26. LDCT lung cancer screening in populations at different risk for lung cancer.
Teles GBDS; Macedo ACS; Chate RC; Valente VAT; Funari MBG; Szarf G
BMJ Open Respir Res; 2020 Feb; 7(1):. PubMed ID: 33371010
[TBL] [Abstract][Full Text] [Related]
27. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.
Katki HA; Kovalchik SA; Petito LC; Cheung LC; Jacobs E; Jemal A; Berg CD; Chaturvedi AK
Ann Intern Med; 2018 Jul; 169(1):10-19. PubMed ID: 29800127
[TBL] [Abstract][Full Text] [Related]
28. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
Tammemägi MC; Darling GE; Schmidt H; Llovet D; Buchanan DN; Leung Y; Miller B; Rabeneck L
Lung Cancer; 2021 Jun; 156():31-40. PubMed ID: 33887677
[TBL] [Abstract][Full Text] [Related]
29. Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
Pu CY; Lusk CM; Neslund-Dudas C; Gadgeel S; Soubani AO; Schwartz AG
JAMA Oncol; 2022 Mar; 8(3):374-382. PubMed ID: 35024781
[TBL] [Abstract][Full Text] [Related]
30. Protocol and Rationale for the International Lung Screening Trial.
Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
[No Abstract] [Full Text] [Related]
31. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
32. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
[TBL] [Abstract][Full Text] [Related]
33. Economic impact of using risk models for eligibility selection to the International lung screening Trial.
Cressman S; Weber MF; Ngo PJ; Wade S; Behar Harpaz S; Caruana M; Tremblay A; Manser R; Stone E; Atkar-Khattra S; Karikios D; Ho C; Fernandes A; Yi Weng J; McWilliams A; Myers R; Mayo J; Yee J; Yuan R; Marshall HM; Fong KM; Lam S; Canfell K; Tammemägi MC
Lung Cancer; 2023 Feb; 176():38-45. PubMed ID: 36592498
[TBL] [Abstract][Full Text] [Related]
34. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
[TBL] [Abstract][Full Text] [Related]
35. Selection of eligible participants for screening for lung cancer using primary care data.
O'Dowd EL; Ten Haaf K; Kaur J; Duffy SW; Hamilton W; Hubbard RB; Field JK; Callister ME; Janes SM; de Koning HJ; Rawlinson J; Baldwin DR
Thorax; 2022 Sep; 77(9):882-890. PubMed ID: 34716280
[TBL] [Abstract][Full Text] [Related]
36. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B; Eldridge RC; Pfeiffer RM; Shiels MS; Kemp TJ; Guillemette C; Hartge P; Sherman ME; Brinton LA; Black A; Chaturvedi AK; Hildesheim A; Berndt SI; Safaeian M; Pinto L; Wentzensen N
Int J Cancer; 2017 Feb; 140(3):600-610. PubMed ID: 27770434
[TBL] [Abstract][Full Text] [Related]
37. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
38. Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria-Reducing Race Disparities.
Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
JTO Clin Res Rep; 2021 Mar; 2(3):100137. PubMed ID: 34590000
[TBL] [Abstract][Full Text] [Related]
39. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
